WAPDA's Mohammad Yasir Sultan poses with the National Athletics Championships gold medal after winning the men's Javelin throw final at the NED University in Karachi on October 23, 2026. — ...
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...
The company that operates an immigrant detention center in Aurora asked a court Friday to change the venue for a lawsuit over a weeks-long standoff with state and local public health authorities. GEO ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Chintan Shah is the President and Managing Partner at KNB Communications, a multi-award ...
GEO Group, the corporation that operates immigrant detention facilities nationwide and in Colorado, filed a lawsuit against the state Monday to stop enforcement of a new law which requires regular ...
When George Zoley, the founder of a private company that manages more than 20 federal immigration facilities testified before Congress in 2020, he spoke about how his own immigrant experience shaped ...
Newark Mayor Ras Baraka is calling for the immediate closure of Delaney Hall, which has been at the center of ongoing protests. "After last night's protest without a single arrest, we are lifting this ...
NEWARK, New Jersey (WABC) -- Newark Mayor Ras Baraka announced Tuesday that the city is filing a lawsuit against the operators of Delaney Hall to close the detention center due to reports of health ...
Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC. In the phase 1/2 trial, daraxonrasib ...
Kestrel today announced that the first patient has been dosed in its phase 1 trial of KST-6051, an oral small molecule meant to inhibit multiple different kinds of KRAS mutations. (iStock / Getty ...